CombinatoRX Up 17% on Positive Phase 2 Study
CombinatoRX Inc (CRXX) announced early Monday that its rheumatoid arthritis drug, CRx-102, showed positive phase 2 results.
CRx-102 had a significant statistical difference compared to placebo for both primary and secondary endpoints.
The drug works by increasing the steroid prednisolone's anti-inflammatory activity while controlling its side effects. It has shown great results in three clinical trials up to date, including a study on hand osteoarthritis.
Shares of CombinatoRX are already up more than 17% in pre-market action.
_
CombinatoRX Inc (CRXX) announced early Monday that its rheumatoid arthritis drug, CRx-102, showed positive phase 2 results.
CRx-102 had a significant statistical difference compared to placebo for both primary and secondary endpoints.
The drug works by increasing the steroid prednisolone's anti-inflammatory activity while controlling its side effects. It has shown great results in three clinical trials up to date, including a study on hand osteoarthritis.
Shares of CombinatoRX are already up more than 17% in pre-market action.
_
posted by Nico at
7:43 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home